Very interesting thank you - also thinking of 2 studies may 2026The strongest human data comes from a 2026 study in Frontiers in Immunology that demonstrated melatonin increases intracellular glutathione in human immune cells (ILC2s).
Frontiers
This study showed:
Melatonin elevated glutathione levels in human ILC2s from five different donor samples
Frontiers
The mechanism involved upregulation of GCLC (the rate-limiting enzyme in glutathione synthesis) and NRF2 activation
Frontiers
Blocking glutathione synthesis prevented melatonin's anti-inflammatory effects, confirming glutathione was essential to melatonin's action
The other is a 2006 study
Reduced oxidative damage in ALS by high-dose enteral melatonin treatment"
Citation:
National Institutes of Health
This was published in the Journal of Pineal Research in 2006. The study is particularly relevant because it specifically tested 300 mg daily rectal melatonin as a treatment approach.( avoids first pass and liver)
Key Findings
Safety Profile: Chronic high-dose (300 mg/day) rectal melatonin was well tolerated during an observation period of up to 2 years in 31 ALS patients.
National Institutes of Health
Oxidative Stress Reduction: The study found that serum protein carbonyls (a marker of oxidative stress) were elevated in ALS patients but normalized to control values by melatonin treatment.
National Institutes of Health
Study Design: The research combined:
Cultured motoneuron cell studies
Genetic mouse models of ALS (SOD1(G93A)-transgenic)
Clinical safety trial in ALS patients
Connection to Glutathione
The study demonstrates melatonin's role in reducing oxidative stress, which is closely related to the glutathione antioxidant system. Melatonin acts as a powerful antioxidant that works through multiple mechanisms, including enhancing antioxidant enzyme activity like glutathione peroxidase.
This is a fascinating intersection of genetics, lipid biology, oxidative stress, and neurodegeneration. APOE4 is particularly interesting as its effects appear to extend beyond simply altering Alzheimer’s disease risk; it can influence lipid transport, neuronal function, inflammation, and the brain’s response to metabolic stress.
As a physician-scientist, I think the key challenge is translating these mechanistic insights into interventions that are genuinely personalized. A biologically plausible pathway involving oxidized lipids or redox balance does not automatically mean that supplementing with an antioxidant such as NAC will improve clinical outcomes, particularly in people with APOE4.
What I find most promising is the possibility of moving beyond genetic risk as a static label. If we can understand how APOE genotype interacts with modifiable factors (metabolic health, vascular function, sleep, inflammation, diet, and lipid biology) we may be able to identify individualized pathways for risk reduction. The future of dementia prevention may ultimately be less about treating a single gene and more about understanding the biological environment in which that gene operates.
Hi Kim, I don't like to suggest specific protocols or supplements - I share what I stumble on in my research to keep my own genes in check. That said, I personally use NAC (along with glycine) in my daily stack.
Hi Karin, these sound logical. I’m just lately wondering if magnesium ( glycinate maybe especially L-threonine form ) might compete with Lithium for the binding site inhibiting gsk3beta? I asked Nick to look at this with a specific paper in my comment for his view but I think he may have a lot on at this moment and wondering if you had thoughts or might consider also asking for a balanced viewpoint as I think of Lithium orotate as foundational ?
Thanks, that’s how I am currently taking it , the Claude advice was that higher Li concentration vs magnesium helped occupy binding site as no kinetic binding studies available and suggestion was to possibly increase the Lithium to 10-15mg in morning which might reduce the interaction and unlikely to cause sfx at that dose and maybe intermittent use of Magnesium L-threonate for sleep etc if needed.
Very interesting thank you - also thinking of 2 studies may 2026The strongest human data comes from a 2026 study in Frontiers in Immunology that demonstrated melatonin increases intracellular glutathione in human immune cells (ILC2s).
Frontiers
This study showed:
Melatonin elevated glutathione levels in human ILC2s from five different donor samples
Frontiers
The mechanism involved upregulation of GCLC (the rate-limiting enzyme in glutathione synthesis) and NRF2 activation
Frontiers
Blocking glutathione synthesis prevented melatonin's anti-inflammatory effects, confirming glutathione was essential to melatonin's action
The other is a 2006 study
Reduced oxidative damage in ALS by high-dose enteral melatonin treatment"
Citation:
National Institutes of Health
This was published in the Journal of Pineal Research in 2006. The study is particularly relevant because it specifically tested 300 mg daily rectal melatonin as a treatment approach.( avoids first pass and liver)
Key Findings
Safety Profile: Chronic high-dose (300 mg/day) rectal melatonin was well tolerated during an observation period of up to 2 years in 31 ALS patients.
National Institutes of Health
Oxidative Stress Reduction: The study found that serum protein carbonyls (a marker of oxidative stress) were elevated in ALS patients but normalized to control values by melatonin treatment.
National Institutes of Health
Study Design: The research combined:
Cultured motoneuron cell studies
Genetic mouse models of ALS (SOD1(G93A)-transgenic)
Clinical safety trial in ALS patients
Connection to Glutathione
The study demonstrates melatonin's role in reducing oxidative stress, which is closely related to the glutathione antioxidant system. Melatonin acts as a powerful antioxidant that works through multiple mechanisms, including enhancing antioxidant enzyme activity like glutathione peroxidase.
So interesting! Thank you!!
This is a fascinating intersection of genetics, lipid biology, oxidative stress, and neurodegeneration. APOE4 is particularly interesting as its effects appear to extend beyond simply altering Alzheimer’s disease risk; it can influence lipid transport, neuronal function, inflammation, and the brain’s response to metabolic stress.
As a physician-scientist, I think the key challenge is translating these mechanistic insights into interventions that are genuinely personalized. A biologically plausible pathway involving oxidized lipids or redox balance does not automatically mean that supplementing with an antioxidant such as NAC will improve clinical outcomes, particularly in people with APOE4.
What I find most promising is the possibility of moving beyond genetic risk as a static label. If we can understand how APOE genotype interacts with modifiable factors (metabolic health, vascular function, sleep, inflammation, diet, and lipid biology) we may be able to identify individualized pathways for risk reduction. The future of dementia prevention may ultimately be less about treating a single gene and more about understanding the biological environment in which that gene operates.
Thank you!
Thank you Karen, are you suggesting ongoing use of NAC at a moderate dose of maybe 600 mg?
Hi Kim, I don't like to suggest specific protocols or supplements - I share what I stumble on in my research to keep my own genes in check. That said, I personally use NAC (along with glycine) in my daily stack.
Hi Karin, these sound logical. I’m just lately wondering if magnesium ( glycinate maybe especially L-threonine form ) might compete with Lithium for the binding site inhibiting gsk3beta? I asked Nick to look at this with a specific paper in my comment for his view but I think he may have a lot on at this moment and wondering if you had thoughts or might consider also asking for a balanced viewpoint as I think of Lithium orotate as foundational ?
don't know what paper you are referring to - but - if that's a concern you can always take lithium morning and magnesium in the evening.
Thanks, that’s how I am currently taking it , the Claude advice was that higher Li concentration vs magnesium helped occupy binding site as no kinetic binding studies available and suggestion was to possibly increase the Lithium to 10-15mg in morning which might reduce the interaction and unlikely to cause sfx at that dose and maybe intermittent use of Magnesium L-threonate for sleep etc if needed.
Hi Karin! Marlene Bailey here!
I am so grateful to have found you again!
Your information is beyond valuable!